According to the vaccine alliance, GAVI, the US vaccine maker Novavax and the Serum Institute of India have signed a memorandum of understanding for the supply of Covid-19 vaccines to the WHO backed Covax facility.
The Serum Institute of India and Novavax already have an agreement for vaccine supply that includes a commitment to provide a total of 1.1 billion doses of Novavax’s candidate NVXCoV2373 to the Covax facility, this existing agreement is to be included in the memorandum of understanding.
The Novavax vaccine is said to have shown 90% efficacy in phase 3 clinical trials in the UK. More than 15000 participants aged 18-84 years enrolled for the trial, out of which 27% were over 65. The efficacy of the vaccine against the group detected with the South African strain was 60%.
Seth Berkley, CEO of GAVI said that this new agreement has brought the Covax facility a step closer to its goal of supplying vaccines globally to end this acute phase of the pandemic. The 1.1 billion cumulative volume of doses are to be made available to the facility after a final advance purchase agreement with Novavax is signed.